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Abstract
Background: Gastrointestinal stromal tumors (GISTs) are common mesenchymal neoplasms in the gastrointestinal
tract of humans and dogs. Little is known about the pathogenesis of these tumors. This study evaluated the role of
c-KIT in canine GISTs; specifically, we investigated activating mutations in exons 8, 9, 11, 13, and 17 of c-KIT and
exons 12, 14, and 18 of platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), all of which have
been implicated in human GISTs.
Methods: Seventeen canine GISTs all confirmed to be positive for KIT immunostaining were studied. Exons 8, 9, 11,
13 and 17 of c-KIT and exons 12, 14, and 18 of PDGFRA, were amplified from DNA isolated from formalin-fixed
paraffin-embedded samples.
Results: Of these seventeen cases, six amplicons of exon 11 of c-KIT showed aberrant bands on gel
electrophoresis. Sequencing of these amplicons revealed heterozygous in-frame deletions in six cases. The
mutations include two different but overlapping six base pair deletions. Exons 8, 9, 13, and 17 of c-KIT and exons
12, 14, and 18 of PDGFRA had no abnormalities detected by electrophoresis and sequencing did not reveal any
mutations, other than synonymous single nucleotide polymorphisms (SNPs) found in exon 11 of c-KIT and exons
12 and 14 of PDGFRA.
Conclusions: The deletion mutations detected in canine GISTs are similar to those previously found in the
juxtamembrane domain of c-KIT in canine cutaneous mast cell tumors in our laboratory as well as to those
reported in human GISTs. Interestingly, none of the other c-KIT or PDGFRA exons showed any abnormalities in our
cases. This finding underlines the critical importance of c-KIT in the pathophysiology of canine GISTs. The
expression of KIT and the identification of these activating mutations in c-KIT implicate KIT in the pathogenesis of
these tumors. Our results indicate that mutations in c-KIT may be of prognostic significance and that targeting KIT
may be a rational approach to treatment of these malignant tumors. This study further demonstrates that
spontaneously occurring canine GISTs share molecular features with human GISTs and are an appropriate model
for human GISTs.
Background
Gastrointestinal stromal tumors (GISTs) are one of the
most common mesenchymal tumors that arise from the
wall of the gastrointestinal tract. Gastrointestinal stro-
mal tumors occur in many species including humans,
dogs [1-3], and horses [4,5]. GISTs can metastasize to
the liver and peritoneal cavity, warranting a very poor
prognosis. In humans, approximately 70% of GISTs
occur in the stomach and 20% occur in the small
intestine [6,7], whereas in dogs the reverse is true with
76% of GISTs occurring in the small intestine and
colon, while 19% occur in the stomach [2].
The majority of GISTs are diagnosed by the demonstra-
tion of the expression of KIT (CD117), a type III tyrosine
kinase receptor encoded by the proto-oncogene c-KIT
[2,8-11]; although a small proportion of GISTs do not
exhibit CD117 immunoreactivity [12]. KIT has critical
roles in cell differentiation, proliferation and migration,
especially in hematopoietic, neural crest, and germ cell
lineages [13]. In addition, KIT along with its ligand, stem
cell factor (SCF), also known as steel factor, is necessary
for the development of melanocytes, mast cells, and
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GISTs may originate from the interstitial cells of Cajal,
which are pacemaker cells responsible for regulating peri-
stalsis in the gastrointestinal tract [15,16].
The KIT receptor is a cell surface receptor consisting
of an extracellular domain, a transmembrane domain,
and a cytoplasmic domain, which includes the juxta-
membrane and kinase domains [17,18]. The juxtamem-
brane domain (amino acid residues 543-580) [13] is a
highly conserved region of KIT located between the
transmembrane domain (amino acid residues 521-543)
[17] and kinase domain (amino acid residues 581-936)
[13]. The KIT juxtamembrane domain is primarily
coded for by exon 11 of c-KIT, while the split kinase
domain are coded for by exons 12-18 of c-KIT [19]. The
juxtamembrane domain regulates the enzymatic activity
of KIT by preventing relative movement of the protein
and thus inhibiting receptor dimerization [20]. In nor-
mal cells, binding of the SCF ligand to the KIT receptor
results in receptor homodimerization and subsequent
activation of the KIT receptor via cross phosphorylation
of tyrosine residues on the opposite KIT homodimer
partner [20]. The phosphotyrosines become binding
sites and activators of several cell-signaling proteins
including JAK2 and PI3K [21]. These particular proteins
are the start of the JAK-STAT and JNK pathways, lead-
ing to a potent intracellular signal for the cell to prolif-
erate [21,22]. Gain-of-function mutations in KIT among
human GISTs have demonstrated that the constitutive
activation of KIT in the absence of its ligand and with-
out dimerization may play a critical role in GIST tumor-
igenesis [23].
In humans, mutations in c-KIT have been reported in
more than 65% of GIST cases [8,20,23,24], and in
GISTs with wild-type c-KIT, mutations of platelet-
derived growth factor receptor, alpha polypeptide
(PDGFRA) were found in 35% of those cases [25].
PDGFRA codes for a transmembrane type III tyrosine
kinase receptor for members of the platelet-derived
growth factor family, which are mitogens for cells of
mesenchymal origin. GISTs with c-KIT or PDGFRA
mutations have similar downstream signaling pathways,
suggesting that PDGFRA mutations serve as an alterna-
tive tumorigenic mechanism to c-KIT in GISTs [25].
Mutations have been found in exons 11, 9, 13, and 17
of c-KIT in sporadic GISTs, with exon 11, the juxta-
membrane domain, being the most frequent site of
mutations [16,26,27], comprising up to 90% of all c-KIT
mutations [28]. Exon 8 of c-KIT has been reported to
have mutations in other types of neoplasias. Most
GISTs are sporadic, but familial GIST syndromes pre-
senting with multiple GISTs have been reported in
humans [29]. Affected family members often harbor
germline mutations of the c-KIT gene in their tumors
and leukocytes [29,30] and there is a report of one
family with a germline mutation in PDGFRA [31]. The
familial GIST syndrome has been recapitulated in two
knock-in mouse models, one designed with a V558
deletion mutation in exon 11 of c-KIT,a n dt h eo t h e r
carrying a K-to-E amino acid mutation at position 641
in exon 13 of c-KIT [32,33].
All of the reported mutations in c-KIT could poten-
tially lead to the activation of KIT in the absence of its
ligand. Constitutively activated KIT would then give
rise to the development and/or progression of gastro-
intestinal stromal tumors in dogs. A comparison of the
currently documented mutations found in c-KIT in
humans and canines is presented in Figure 1. The
reported canine c-KIT mutations have been associated
with mast cell tumors [34,35] as well as GISTs [2].
The purpose of this study was to evaluate the role of
c-KIT and PDGFRA in canine GISTs. While KIT
immunopositivity has been demonstrated in canine
GISTs in two previous studies [2,3], only the study by
Frost et al. has explored mutations in c-KIT to date,
Figure 1 Comparison of c-KIT mutations in human and canine
GISTs. Human mutations are in white [8,9,21]; dog mutations are
indicated in gray [2,3]. Codon numbering is based upon the human
amino acid sequence [GenBank: NP_000213]. The asterisk indicates
the two deletion mutations found in this study.
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revealing mutations in exon 11 of c-KIT in two of the
cases. Our present study investigates exons 8, 9, 11,
13, and 17 of c-KIT and exons 12, 14, and 18 of
PDGFRA for mutations in a larger sample set of canine
GISTs, providing information on c-KIT mutational sta-
tus in seventeen cases.
Methods
Cases
Forty-six cases of canine gastrointestinal smooth muscle
tumors were submitted to the Michigan State University
Diagnostic Center for Population and Animal Health
from 1991 to 2006. All tumors originated from surgical
biopsies that were immediately fixed in 10% neutral buf-
fered formalin and embedded in paraffin within 24-48
hours, following routine protocols. From this pool of
cases eighteen tumors were diagnosed as GISTs con-
firmed by characteristic histomorphology and positive
KIT staining by immunohistochemistry and were
included in this study (Figures 2a and 2b). The age of
the dogs in this study ranged from 4 to 15 years with a
mean age of 10.9 years. Various purebred and mixed
bred dogs were included with a gender ratio of 72%
female to 28% male dogs. Tumor sites were distributed
throughout the gastrointestinal tract from the stomach
to the cecum as indicated in Table 1. A histologically
normal, non-neoplastic tissue sample from each dog was
also analyzed to determine the c-KIT mutation status in
constitutive DNA.
Figure 2 GIST. 2a - Section of a gastrointestinal stromal tumor
analyzed in this study stained with hematoxylin and eosin. 2b - The
same gastrointestinal stromal tumor with immunohistochemical
staining showing abundant KIT expression as reflected by the
brown deposits.
Table 1 Samples
Case Breed Age Sex Tumor Site c-KIT Mutations PDGFRA Mutations
1 Cockapoo 13 FS stomach exon 11 deletion, exon 11 SNP normal
2 German Wirehaired Pointer 10.5 FS cecum exon 11 deletion exon 12 SNP, exon 14 SNP
3 Cocker Spaniel 12 FS small intestine normal normal
4 Labrador Retriever 4 FS duodenum normal normal
5 American Pit Bull Terrier 15 FS cecum exon 11 deletion normal
6 Golden Retriever 13 F small intestine normal normal
7 Collie 12 M jejunum exon 11 SNP normal
8 Boxer 10 M jejunum normal normal
9 Cocker Spaniel US FS small intestine exon 11 SNP normal
10 Irish Setter 11 FS small intestine normal normal
11 Golden Retriever 10.5 MN cecum exon 11 SNP normal
12 Springer Spaniel 10.6 FS cecum exon 11 deletion normal
13 Labrador Retriever 8.5 FS jejunum normal normal
14 German Shorthaired Pointer 9 FS small intestine normal exon 12 SNP
15 Labrador Retriever cross 10 MN ileocecocolic junction exon 11 deletion normal
16 Mixed 9 FS cecum exon 11 deletion exon 12 SNP, exon 14 SNP
17 Mixed 15 MN jejunum normal normal
Signalment and site of canine gastrointestinal stromal tumor cases analyzed in this study. FS = female spayed, MN = male neutered, US = unspecified.
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Page 3 of 9DNA isolation from formalin- fixed paraffin-embedded
(FFPE) sections
Neoplastic tissue, less than 1 mm
3, was excised from each
FFPE block to retrieve sections corresponding to KIT
positive immunostaining areas. Similarly, sections of his-
tologically normal tissue, negative for KIT immunostain-
ing were also collected from each case. From these tissue
sections DNA was isolated as described previously
[34,36]. The tissue section was placed in 400 μlo fd i g e s -
tion buffer (50 mM Tris, pH 8.5, 1 mM ethylenediamine-
tetraacetic acid [EDTA], 0.5% Tween) and heated to 95°C
for 10 minutes to melt the paraffin. The tissue solutions
were then subjected to high power microwave irradiation
twice for 30 seconds each with vortexing after each heat-
ing step. After cooling, 5 μl of 15 mg/ml proteinase K
was added to each solution and incubated overnight at
42°C. Following protein digestion, proteinase K was inac-
tivated at 95°C for 10 minutes. The solutions were then
centrifuged and 150 μl was aliquoted to be used as DNA
template in subsequent polymerase chain reaction (PCR).
Amplification of c-KIT juxtamembrane and kinase
domains
Exon 11, coding for the juxtamembrane domain of KIT,
and exon 17, coding for the kinase domain of KIT, were
amplified from these tissue sections via PCR using pri-
mers and conditions optimized in earlier studies [37,38].
Exon 8, 9, and 13 of c-KIT and exons 12, 14, and 18 of
PDGFRA were also amplified (Table 2). The PCRs were
set-up in 25 μl total reaction volume consisting of 50 ng
of DNA template prepared as described above: 5 pmol
of each primer, 0.5 U of Taq polymerase (Invitrogen,
Carlsbad, CA) and final concentrations of 80 μM deoxy-
nucleoside triphosphate, and 2 mM MgCl2. Cycling con-
ditions for the PCR were 94°C for 4 minutes; 40 cycles
of 94°C for 1 minute, annealing temperatures averaging
58°C for 1 minute, and 72°C for 1 minute; followed by a
final elongation step at 72°C for 5 minutes. PCR pro-
ducts were then subjected to electrophoresis on 2%
agarose gels and visualized under ultraviolet light after
ethidium bromide staining.
Sequencing
Amplified fragments from all tissue sections were char-
acterized by automated sequencing. The PCR product
for each section was submitted in 5 μl quantities with
30 pmol of the appropriate primer to Michigan State
University’s Genomics Technology Support Facility. This
facility utilizes the automated direct sequencing techni-
que, which incorporates fluorescently labeled dideoxynu-
cleotides during cycle sequencing and separates the
resulting products by capillary electrophoresis for detec-
tion on an ABI 3700 sequence analyzer (Foster City,
CA).
Results
Of the eighteen KIT immunopositive cases, seventeen
cases yielded amplification products. The remaining case
did not yield amplification products with any of the c-
KIT or PDGFRA primer sets or with primers for unre-
lated canine genes.
For exon 11 of c-KIT, six of these seventeen cases of
canine GISTs displayed an aberrant banding pattern
upon gel electrophoresis of the PCR product (Figure 3).
The remaining eleven cases displayed a band similar to
the positive control on electrophoresis, and analysis con-
firmed the sequence was identical to the wild-type exon
11 of c-KIT except for a single nucleotide polymorphism
(SNP) located at base pair 50110905 C > T [GenBank:
NC_006595.2] detected in four cases. However,
sequence analysis of the aberrant six cases uncovered a
mixture of normal and mutant alleles. Further examina-
tion identified short in-frame deletions (Figure 4). The
mutations included two different, but overlapping 6 base
pair deletions, which translated to a deletion of two
amino acids in two of the cases and an amino acid
change and a deletion of two amino acids in the other
four cases. The first mutation (canine codons 556-557)
occurred in two of the cases and consisted of the dele-
tion of the sequence AGTGGA located at base pairs
50110838 to 50110843 of the canine genomic DNA
[GenBank: NC_006595.2]. This mutation translated to a
deletion of two amino acids, tryptophan and lysine, at
Table 2 Primer sets
Amplified Region Forward Reverse
c-KIT exon 8 5’-CAGCAGTCTGACCTATGGC -3’ 5’-GCTCAGCTCCTGGACAGAAA-3’
c-KIT exon 9 5’-GATTGATTGATTGATTTTCCTAG-3’ 5’-GCAGGCAGAGCCTAAACATC-3’
c-KIT exon 11 5’-CATTTGTTCTCTACCCTAAGTGCT-3’ 5’-GTTCCCTAAAGTCATTGTTACACG-3’
c-KIT exon 13 5’-CTGATTAAGTCGGATGCGGC-3’ 5’-CAAGCACTGTCGCAATGG-3’
c-KIT exon 17 5’-ATAGCAGCATTCTCGTGTTG-3’ 5’-AACTAAAATCCTTCACTGGACTG-3’
PDGFRA exon 12 5’-TTAATGGCTCTGATTGCTCAC-3’ 5’-CACCCAGTGCTCATAACCTC-3’
PDGFRA exon 14 5’-ACTGGTTTTGGTTCCCACAG -3’ 5’-CAATGATTCGCAGCAACG-3’
PDGFRA exon 18 5’-TAGCTCAGCCGTGGGTATG-3’ 5’-CACATGAGCAGAGATGTCAGG-3’
Primer sets used for the amplification of the indicated exons of c-KIT and PDGFRA during PCR.
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Page 4 of 9codons 556 and 557 of canine KIT, respectively [Gen-
Bank: NP_001003181]. The second mutation (canine
codons 556-558) was discovered in four of the cases and
results in the deletion of the sequence GGAAGG
located at base pairs 50110841 to 50110846 of the
canine genomic DNA [GenBank: NC_006595.2]. This
second mutation translated to a deletion of two amino
acids, lysine and valine, at codons 557 and 558 of canine
KIT, respectively [GenBank: NP_001003181]. The dele-
tion of the last two guanines of the codon 556 in this
mutation combined with deletion of the next 4 nucleo-
tides resulted in an amino acid change from the trypto-
phan at codon 556 to a phenylalanine (Table 3). In
these six cases, analysis of the normal tissue obtained
from these dogs revealed sequences that were identical
to the wild-type exon 11 of c-KIT.
All seventeen cases were also amplified for exons 8,
9, 13, and 17 of c-KIT. Only the expected single band,
similar to the positive control, was observed after gel
electrophoresis. Sequencing of all PCR products
obtained revealed no mutations in these GIST samples
for exons 8, 9, 13, or 17 of c-KIT. Similarly, amplifica-
tion of exons 12, 14, and 18 of PDGFRA in these
GIST samples revealed clear, single bands on electro-
phoresis and the PCR products were directly
sequenced. Three of the cases had a SNP located at
base pair 49690424 A > G [GenBank: NC_006595.2]
in exon 12 of PDGFRA. Two of the cases also had a
S N P sl o c a t e da tb a s ep a i r4 9 6 9 1 3 8 7A>Ga n d
49691411 G > A [GenBank: NC_006595.2] of exon 14
of PDGFRA (Figure 5).
Figure 3 Electrophoresis of PCR product of exon 11 of c-KIT,
juxtamembrane domain. L = 100 bp ladder; 1 = case with normal
exon 11 of c-KIT, confirmed by sequencing; 2 = case with aberrant
banding pattern; + = positive PCR control (normal dog spleen);
- = negative PCR control (water)
Figure 4 Deletion mutations found in exon 11 of c-KIT. Sequence analysis results illustrating the two deletion mutations present in the six
cases with the aberrant banding pattern. This region of exon 11 of canine c-KIT [GenBank: NP_001003181] differs by only one codon from
humans [GenBank: NP_000213].
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This study was able to ascertain c-KIT and PDGFRA
mutational status of seventeen of eighteen KIT positive
canine gastrointestinal stromal tumors, representing a
good amplification success rate of 94% from FFPE tis-
sues. Significantly, the study identified two distinct but
overlapping mutations in exon 11 of c-KIT in the juxta-
membrane domain. This region appears to be a muta-
tional hotspot with an overall incidence of 35.3% in our
study population of canine GISTs. The only other study
of c-KIT mutations in canine GISTs reported mutations
i nt w oo ff o u r( 5 0 % )G I S T s[ 3 ] .H u m a nG I S T sh a v e
higher incidences of c-KIT mutations ranging from 65%
to 92% across exons 8, 9, 11, 13, and 17, a majority of
which occur in the juxtamembrane domain [8,9,23,39].
In our study, no mutations were identified in exons 8, 9,
13, and 17 of c-KIT. None of our cases showed muta-
tions in PDGFRA. Only a single amplification product
was noted from the corresponding normal tissue of each
GIST case, with sequencing verifying the presence of
only the wild type allele in the normal tissue. These
results indicate that all mutations observed arose soma-
tically in each tumor.
Interestingly, these deletion mutations are similar to
those previously found in the juxtamembrane domain of
c-KIT in canine cutaneous mast cell tumors in our
laboratory [34] and others [13]. In a previous study of
21 canine GISTs, DNA suitable for amplification was
recovered from only four cases and then amplified for
the KIT exon 11 of c-KIT, juxtamembrane domain, and
sequenced [2]. Sequencing revealed mutations in two of
the four canine GISTs, one with a 6 base pair deletion,
TGGAAG, and insertion of CAG, predicted to translate
to a deletion of tryptophan and lysine and an insertion
of glycine at codon 556 [2]. This deletion is quite similar
to the mutation at canine codons 556-557 discovered in
Table 3 Deletion mutations found in canine GISTs in this study
Case Codon DNA Mutation Amino Acid
2 556-557 GTA CAG TGG AAG GTT GTT ® GTA C_AG GTT GTT VQWKVV ® VQVV
16 556-557 GTA CAG TGG AAG GTT GTT ® GTA C_AG GTT GTT VQWKVV ® VQVV
1 556-558 GTA CAG TGG AAG GTT GTT ® GTA CAG T TT GTT VQWKVV ® VQFV
5 556-558 GTA CAG TGG AAG GTT GTT ® GTA CAG T TT GTT VQWKVV ® VQFV
12 556-558 GTA CAG TGG AAG GTT GTT ® GTA CAG T TT GTT VQWKVV ® VQFV
15 556-558 GTA CAG TGG AAG GTT GTT ® GTA CAG T TT GTT VQWKVV ® VQFV
The codon numbering is based upon the canine KIT amino acid sequence. The genomic DNA mutations were experimentally determined by direct sequencing
and the altered sequence is underlined in column three. The expected amino acid changes in the protein are provided in column four. [GenBank: NC_006595.2,
GenBank: NP_001003181].
Figure 5 Single nucleotide polymorphisms (SNPs). SNPs, demarcated by the boxed letters, found in exon 11 of c-KIT and exons 12 and 14 of
PDGFRA [GenBank: NC_0006595.2] in the canine GIST samples (R = A or G; Y = C or T).
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discovered by Frost et al. was a substitution of T with C
predicted to replace codon 575 leucine with proline [2].
We did not detect a similar mutation in our study
population. The mutations observed in our study popu-
lation of GISTs were clustered at codons 556-558 of c-
KIT. No gender predilection has been reported in
human GISTs, and the observation of 73% female to
27% male ratio in our study is interesting, but its signifi-
cance needs further evaluation.
A simple deletion identical to the mutation at canine
codons 556-557 in our study has also been reported in
multiple cases of human GISTs [8,24]. In the study by
Taniguchi et al., a deletion and point mutation similar
to the mutation at canine codons 556-558 in our study
was also detected in one of the cases they analyzed [8].
Rubin et al., found the same mutation as the deletion of
canine codons 556-557 in our canine GISTs in 2 of 48
human GISTs, and they reported the same deletion of
canine codons 556-558 in 1 of the 48 cases [9]. In a
study of human familial GISTs, germline deletion muta-
tions were discovered in the same region as the pre-
viously mentioned deletions [29].
All four of the SNPs found in our canine GIST sam-
ples were silent mutations, with no change predicted in
the translated protein. The SNP in exon 12 of PDGFRA
at genomic base pair 49690424 [GenBank:
NC_006595.2], has been reported previously [40].
In humans, GISTs are rare neoplasms. The age-
adjusted incidence of gastric mesenchymal tumors was
0.31 per 100,000 population in 2002, of which 82% were
classified as GISTs [41]. The population incidence of
GISTs is difficult to determine in dogs. Frost et al. com-
mented that in dogs, gastrointestinal neoplasias account
for 12-120 cases per 10,000 neoplasia cases, and in our
study GISTs accounted for 39% of the total number of
gastrointestinal tumors collected during the study period.
Heterozygosity with regard to mutations in the tumor
sections resulted in an easily detectable aberrant band-
ing pattern on agarose gels. While the gel electrophor-
esis used in this study does not resolve the normal
versus the mutant alleles, which differ by only six base
pairs, the normal and mutant alleles formed a heterodu-
plex, which contained a bubble created by the longer
normal allele. The heteroduplex structure is predicted to
generate a drag during gel electrophoresis giving rise to
the higher band and allowing easy detection of this rela-
tively small deletion [42]. We cannot be absolutely cer-
tain that the tumor cells are heterozygous with respect
to the mutation, as the tumor sections contained some
non-neoplastic components such as blood vessels.
Regardless, the aberrant banding is a useful screening
tool for this set of mutations.
Conclusions
These data substantially expand the number of canine
gastrointestinal stromal tumors evaluated for mutations
in c-KIT by previous studies [2]. The mutations we have
found are clustered and consistent with those shown to
be activating mutations in the c-KIT gene of human
tumors [23]. Based on these data, we can conclude that
the nature of c-KIT mutations in GISTs in dogs is simi-
lar to that observed in humans.
The juxtamembrane domain of the KIT gene is a highly
conserved region among mammals [13]. This juxtamem-
brane domain acts as a negative regulator of KIT activa-
tion and thus, when this particular domain is mutated,
the autoinhibition is removed, allowing KIT to be acti-
vated in the absence of the KIT ligand [43]. The residues
we found to be deleted in our cases of canine GISTs are
the very same that Ma et al. determined to increase basal
receptor phosphorylation when mutated in c-KIT [44].
The expression of KIT and the presence of these muta-
tions in c-KIT implicate KIT in the pathogenesis of these
tumors pointing to spontaneous GISTs in the dog being
a relevant model for the human disease. Our results also
indicate that mutations in KIT may be of prognostic and
therapeutic significance in canine GISTs as they are in
canine cutaneous mast cell tumors.
Numerous small molecule inhibitors that target speci-
fic tyrosine kinases, tyrosine kinase inhibitors (TKIs),
have successfully been used for the treatment of human
and canine cancers with mutations in KIT [45,46]. Ima-
tinib mesylate (Gleevec, Novartis, Basel, Switzerland),
has been utilized for its ability to inhibit protein tyrosine
kinases since the Food and Drug Administration
approved it in 2001 for the treatment of Chronic Myelo-
genous Leukemia (CML) [47]. Early trials demonstrated
imatinib was also highly effective against GISTs [10].
Imatinib caused marked tumor response rates and dra-
matically increased survival times in most patients [48]
and has now become the standard of care in the treat-
ment of patients with advanced GISTs [49]. However,
since with prolonged treatment clinical resistance can
develop, most likely due to secondary c-KIT mutations,
a new generation of TKIs, such as sunitinib, have been
successfully introduced [48,50]. Research is ongoing to
treat GISTs with resistance to imatinib and sunitinib
[51]. In dogs, the TKIs Palladia (toceranib), Kinavet
(masitinib), and Gleevec (imatinib) have been success-
fully used in numerous neoplastic diseases [45] and
toceranib (Palladia, Pfizer, New York, NY, USA) and
masitinib (Kinavet, AB Science, Short Hills, NJ, USA)
have been registered for the use in dogs with cutaneous
mast cell tumors [52-54]. In a randomized trial, dogs
with KIT mutations were much more likely to respond
to Palladia than those without KIT mutations [55]. To
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Page 7 of 9our knowledge there are no published data on the treat-
ment of canine GISTs with TKIs. Based upon the data
presented here, we propose that targeting KIT may be a
rational approach to treatment of canine GISTs as well.
In addition, we put forwardt h a tc a n i n eG I S T sa r ea
relevant and accessible model for human GISTs, with
shared molecular pathways that can be targeted for
therapy.
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